Methods for producing lactams from oximes by performing a Beckmann rearrangement using a hierarchical porous aluminophosphate catalyst having interconnected microporous and mesoporous networks are provided. Exemplary catalysts include a plurality of weak Brnsted acid active sites, including silicon-containing aluminophosphates having the IZA framework code AFI, such as SAPO-5, CHA, such as SAPO-34, and FAU, such as SAPO-37.

Methods for producing lactams from oximes by performing a Beckmann rearrangement using a hierarchical porous aluminophosphate catalyst having interconnected microporous and mesoporous networks are provided. Exemplary catalysts include a plurality of weak Brnsted acid active sites, including silicon-containing aluminophosphates having the IZA framework code AFI, such as SAPO-5, CHA, such as SAPO-34, and FAU, such as SAPO-37.

The present disclosure features a strain-promoted [2+2+2] reaction that can be carried out under physiological conditions. In general, the reaction involves reacting a pi-electrophile with a low lying LUMO with a quadricyclane on a biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo and in vitro. The reaction is compatible with modification of living cells. In certain embodiments, the pi-electrophile can comprise a molecule of interest that is desired for delivery to a quadricyclane-containing biomolecule via [2+2+2] reaction.

The present disclosure features a strain-promoted [2+2+2] reaction that can be carried out under physiological conditions. In general, the reaction involves reacting a pi-electrophile with a low lying LUMO with a quadricyclane on a biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo and in vitro. The reaction is compatible with modification of living cells. In certain embodiments, the pi-electrophile can comprise a molecule of interest that is desired for delivery to a quadricyclane-containing biomolecule via [2+2+2] reaction.

The present invention relates to a purification method for laurolactam, and more particularly, to a purification method capable of obtaining high-purity laurolactam substantially free of impurities.

The present invention provides a purification method for laurolactam from a reaction product of a laurolactam synthesis process, the production method including: (S1) obtaining a first mixed solid by separating and removing low-boiling point materials through distillation of the reaction product; (S2) removing impurities suspended in a first mixed solution obtained by dissolving the first mixed solid in a good solvent; (S3) obtaining a second mixed solid precipitated by adding a poor solvent to the first mixed solution from which the impurities are removed; and (S4) evaporating a melt obtained by heating and melting the second mixed solid to obtain laurolactam in a gas phase and performing crystallization.

The present invention relates to a purification method for laurolactam, and more particularly, to a purification method capable of obtaining high-purity laurolactam substantially free of impurities.

The present invention provides a purification method for laurolactam from a reaction product of a laurolactam synthesis process, the production method including: (S1) obtaining a first mixed solid by separating and removing low-boiling point materials through distillation of the reaction product; (S2) removing impurities suspended in a first mixed solution obtained by dissolving the first mixed solid in a good solvent; (S3) obtaining a second mixed solid precipitated by adding a poor solvent to the first mixed solution from which the impurities are removed; and (S4) evaporating a melt obtained by heating and melting the second mixed solid to obtain laurolactam in a gas phase and performing crystallization.

The present invention relates to a laurolactam preparation method, a synthesizing device therefor, a laurolactam composition prepared thereby, and a polylaurolactam preparation method using the laurolactam composition, the laurolactam preparation method comprising the steps of: a) synthesizing cyclododecanone oxime into laurolactam through a Bechmann rearrangement in the presence of a catalyst; b) mixing the laurolactam synthesized in step a) in a good solvent and removing the catalyst; and c) mixing the laurolactam, from which the catalyst was removed in step b), in a poor solvent and recrystallizing same.

The present invention relates to a laurolactam preparation method, a synthesizing device therefor, a laurolactam composition prepared thereby, and a polylaurolactam preparation method using the laurolactam composition, the laurolactam preparation method comprising the steps of: a) synthesizing cyclododecanone oxime into laurolactam through a Bechmann rearrangement in the presence of a catalyst; b) mixing the laurolactam synthesized in step a) in a good solvent and removing the catalyst; and c) mixing the laurolactam, from which the catalyst was removed in step b), in a poor solvent and recrystallizing same.

The present invention provides modified cycloalkyne compounds; and method of use of such compounds in modifying biomolecules. The present invention features a cycloaddition reaction that can be carried out under physiological conditions. In general, the invention involves reacting a modified cycloalkyne with an azide moiety on a target biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provide for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).

The present invention provides chimeric compounds that modulate protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, TNF-alpha activity, CK1-alpha activity and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions, such as cytokine-mediated diseases, disorders, and conditions, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant rejection, and cancer, are provided.